Pasireotide monotherapy in Cushing's disease: a single-centre experience with 5-year extension of phase III Trial.
MacKenzie Feder, Jessica; Bourdeau, Isabelle; Vallette, Sophie; Beauregard, Hugues; Ste-Marie, Louis-Georges; Lacroix, André.
; 17(6): 519-29, 2014 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-24287689
SOM230: a new therapeutic modality for Cushing's disease.
Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.
Prevalence of self-reported side effects in neuroendocrine tumour patients prescribed somatostatin analogues.
A 12-month phase 3 study of pasireotide in Cushing's disease.
Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing's disease: results from an open-ended, open-label extension trial.
A Single-Center 10-Year Experience with Pasireotide in Cushing's Disease: Patients' Characteristics and Outcome.
A Practical and Total Synthesis of Pasireotide: Synthesis of Cyclic Hexapeptide via a Three-Component Condensation.
Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors.
Role of somatostatin analogues in the treatment of neuroendocrine tumors.